Please Wait
Applying Filters...
menu
    • menu
    Excipient Market Overview: Clariant sets up its first PEG excipients facility in US; India harmonizes 22 excipient monographs

    DATA COMPILATION
    #PharmaFlow

    Pipeline Prospector March 2026 highlights: Lilly to acquire Centessa for US$ 7.8 bn; Merck buys Terns Pharma for US$ 6.7 bn

    Stock Recap
    #PipelineProspector

    Menu

    013TE6E4WV

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,787Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to download the data

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name Registration No. Compound Registration Date Manufacturer Manufacturer's Country Manufacturer's Address
    31/03/2026 Esteve Quimica
    Spain
    		 Gilead Sciences Korea Ltd. Su6273-5-ND Ledipasvir 2015-10-12 Esteve Quimica, SA Spain C/ Ter, 94 Polígon Industrial 17460 Celrà (Girona), Spain
    31/03/2026 Yuhan Corporation
    South Korea
    		 Gilead Sciences Korea Ltd. Su6273-3-ND Ledipasvir 2015-08-26 Yuhan Chemical South Korea 45 Jiwon-ro, Danwon-gu, Ansan-si, Gyeonggi-do
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.